Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2023
Filter by date:
Showing 1262 press releases before 2023
-
Lynparza plus abiraterone reduced risk of disease progression by 34% vs. standard-of-care in 1st-line metastatic castration-resistant prostate cancer
-
Full-year and Q4 2021 results
-
Imfinzi plus chemotherapy reduced risk of death by 20% in 1st-line advanced biliary tract cancer
-
Imfinzi plus tremelimumab demonstrated unprecedented survival in 1st-line unresectable liver cancer with 31% of patients alive at three years
-
Enhertu granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
-
AstraZeneca aims to redefine liver, biliary tract and prostate cancer treatment with practice-changing Imfinzi and Lynparza data at ASCO GI and GU
-
AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against ‘undruggable’ targets
-
New Vaxzevria data further support its use as third dose booster
-
template 2022
-
AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006
Latest articles and press releases
All of our latest press releases and articles are available to explore
Use a maximum of two downloads here
